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POSTTRANSPLANT Iymphoproliferative disorders (PTLDs) encompass a range of benign to frankly 
malignant lymphoid tumors that occur in the immunocom-
promised state. I Many. but not all. are of B-Iymphocyte 
origin and the Epstein-Barr virus is acknowledged to be an 
important cofactor in most cases. 
The introduction of cyclosporine A (CyA) in the early 
1980s brought with it concerns that this new immunosup-
pressant might also cause an inevitable increase In the 
number of transplant lymphomas. 2 These fears were not 
borne out. and PTLDs presently occur in about ~ of 
transplant recipients. 
FK 506 is a new macrolide immunosuppressant that has 
been shown to be at least 100 times more potent than CyA 
by in vitro assays.3 .• It is appropriate. therefore. to again 
ask whether or not the degree of immunosuppression 
exerted by such a powerful new drug carries with it an 
unacceptable price in the fonn of increases in the fre-
quency or aggressiveness of transplant-associated lympho-
mas. 
MATERIALS AND METHODS 
Patient Population 
Between March I. 1989 and July I. 1990.679 patients recel\ed FK 
S06 at the Univer;ity of Pittsburgh. An additional 100 or so 
patients are currently enrolled in a randomized trial of FK 506 vs 
CyA. and will not be included in the statistics. No PTLDs have 
been seen in that trial. however. Of the 679 patients. thert Y"ere 
516 liver recipients. 72 renal recipients. 40 patients who re~eived 
liver; with I or more other orpns. 30 heart transplant p<:!JCnts. 
and 21 miscellaneous patients. 
During the study period a total of 19 PTLDs were dia~edK 
Five of these occurred in pallents who were taking FK 506-
containing regimens; the remainder were under CyA-based IlIllllU-
nosuppression. An additional seven patients who had had previ-
ously diagnosed PTLD were also switched over to FK 506 during 
this time. 
The relationship of FK 506 to the development and beha\)Of of 
PTLDs was studied by subdividing the patients into three main 
groups. Group I patients received FK 506 as primary immuno-
suppression for their organ transplants and subsequently devel-
oped PTLD. Group 2 patients were converted from CyA regimen 
to FK 506 because of either intractable rejection or Cy A toticity. 
They had no evidence of PTLD prior to the switchovCf. but 
subsequently went on to develop a Iymphoproliferation. Group 3 
patients were switched over to FK S06 with no prior docu~nted 
PTLD. 
Pathological Studies 
Routinely processed surgical and autopsy specimens were re-
viewed by one of us (M.N.). ClooaJ analysis is based on i~ 
cytochemical studies done as a pan of the pathological evaluation. 
Immunoger1Olypic data are not available at present on the~ ca~sK 
Like\\;se. EB\' serologic data were used when available from the 
medical record. 
RESULTS 
Frequency of PTLD Arising Under FK 506 
The median ivllow-up time for patients receiving FK 506 is 
10.5 months. with a range of I to 16 months. During this 
time. three patients in group I (primary FK) and two 
patients in group 2 (switchover to FK 506) developed 
Iymphoproliferative processes. for a frequency of 0.7%. 
PTLD in Transplant Recipients Initially Receiving FK 506-
Based Immln:lsuppression (Group 1) 
The three patients who developed PTLD following pri-
mary FK 506 immunosuppression did so at 1.6. 2.6, and 
5.9 months after transplant. Patient 1 was highly sensitized 
and received her first hepatic allograft on December 13. 
1989. She required retransplant 3 days later due to primary 
nonfunction. In addition to FK 506. three courses ofOKD 
and multiple steroid boluses were required to control 
rejection. Silo: developed bacterial sepsis and her second 
liver was restcted at the end of January. AI that time. a 
nonclonal PTLD was found in the allograft liver and 
periponal nodes. The patient expired approximately I 
week follo\llomg this third transplant. with widespread 
nonclonal PTl.D. 
Patient ::! \IIoas an 18-year-old white male who presented 
with a sore throat::! 112 months following his liver trans-
plant. L" nilateral tonsillectomy and adenoidectomy led to a 
diagnosis of polymorphic. polyclonal PTLD. He was 
treated with acyclovir and a reduction of FK 506. He is 
currently well at 7 months after diagnosis. with no evi-
dence of residual disease. 
The final patient in group I developed a phenotypically 
clonal PTLD in her allograft liver approximately 6 months 
after transplant. She presented at that time with fever and 
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hepatic mass and on workup found to have a lO-cm tumor 
with a smaller satellite nodule, confined to the allograft. 
Resection was perfonned. immunosuppression reduced. 
and acyclovir administered. She has remained without 
evidence of disease for 3 months follo\loing tumor resec-
tion. 
PTLD in Patients Switched Over from CyA to FK 506 
(Group 2) 
One of the two patients in group 2 received his first kidney 
in 1982. and by April 1989 had received his third kidney. 
The patient. who was highly sensitized. required CyA. 
Imuran, and repeated courses of OKD and steroids to 
control rejection. On July 14, 1989. he was started on FK 
506 to rescue his kidney. However. renal function contin-
ued to deteriorate. Just before nephrectomy in mid-Sep-
tember, a CT scan showed changes in the mastoid. and a 
mastoidectomy was concurrently performed. Both As-
pergillus and PTLD were found in the mastoid. and the 
allograft kidney contained PTLD. He was removed from 
immunosuppression at the time of allograft nephrectomy. 
but subsequently expired due to Aspergillus brain abscess 
approximately 4 months after tumor diagnosis. No clinical 
evidence of tumor was present at the time of death; 
however. autopsy was declined. 
The second patient was a 5-year-old girl who received a 
liver for treatment of biliary atresia in August 1989 and was 
placed on FK 506 I month later to control accelerated 
rejection. She did well until 8 months following transplant. 
at which time gastric biopsies showed evidence of clonal 
IgA lambda PTLD in that organ. CT of the head. chest. 
and abdomen was negati"e for tumor elsewhere. She 
received IV acyclovir 450 mg q8h and her FK 506 was 
dropped from 3 mg/d to 3 mg every third day. No elevation 
of liver enzymes was obsened. and she has done well for 
the last 4 months. with no e,idence of disease on follow-up 
biopsy. EBV serology at the time of diagnosis was consis-
tent with a primary infection. 
Patients with Prior Documented PTLD Who Were Later 
Switched to FK 506 (Group 3) 
Seven patients who had had prior PTLDs were switched 
over to FK for various reasons. One patient had a mono-
clonal PTLD of the esophagus diagnosed in December 
1987. This required several resections and radiotherapy for 
control. Despite temporary resolution. lesions invariably 
recurred near the same site. Further radiotherapy was 
planned but was canceled in October 1989. At the same 
time. the patient was also switched O\'er to FK 506 for 
control of rejection secondary to the discontinuance of 
CyA. The lesion regressed while the patient was on this 
regimen and he has remained weU without e\;dence of 
tumor for the last \0 months on FK 506. Three other 
patients were switched over to FK 506 for relief of renal 
dysfunction due to CyA. T ... ·o patients had a poor diagno-
sis of clonal PTLD at 75 and 44 months. and one had a 
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diagnosis of nonclonal PTLD at 23 months. prior to FK 
506 administration. ~one of these three patients had 
evidence of tumor at the time FK therapy was begun. No 
evidence of recurrent tumor has been seen with respective 
follow-up intervals of 8.5. 5.5. and 6.0 months. 
Two additional patients had biopsies consistent with 
PTLD from the gut and lung. respectively. but no further 
pathologic studies were performed due to paucity of tissue. 
Both responded to conservative treatment and were 
switched to FK 506 at 3 and 5.5 months after diagnosis. 
Neither had PTLD at the time of the switchover and no 
evidence of tumor has developed at 7 and 11 months 
following the institution of FK-based immunosuppression. 
The final patient was a 11-year-old boy who had PTLD 
present at the time of switchover to FK 506 therapy. He 
expired of DIC a short time thereafter. and at autopsy 
residual PTLD was found in lymph nodes. 
DISCUSSION 
The overall incidence of PTLD for all transplant recipients 
at the University of Pittsburgh is approximately 2O/C. In the 
general population of PTLD patients who did not receive 
FK 506. but almost iO\anably received CyA. the median 
time between transplant and tumor was 6.1 months. and 
65% of the tumors occurred less than 10 months after 
transplant. Thus. the 0.79c frequency of PTLD seen with a 
1O.5-month-median foUow-up time compares fa\'orably 
with the general transplant population. 
The brevity of the follow-up would indicate that the final 
frequency may be somewhat higher than at present. In this 
context. it is important to recall that the intensity of clinical 
surveillance may also introduce an important artifact when 
attempting to compare statistics from different eras. In 
older times. PTLDs \Ioere diagnosed when they were 
clinically and pathologically obvious. With greater aware-
ness and understanding of the spectmm of this complica-
tion. subtle lesions \10 hich would have been missed or 
misdiagnosed as hyperplasia or rejection 10 years ago are 
now diagnosed with accuracy. 
In summarizing our early experience with FK 506. 
several additional features are of interest. First. both 
clonal and nonclonal tumors occur relatively soon after 
transplant. This is similar to PTLDs occurring with CyA-
based regimens. ~ I n contrast. azathioprine-based regimens 
tend to produce early nonclonal disease. with clonal tu-
mors arising some yeaTS following transplant.5 The simi-
larity to the Cy A time course should not be surprising. 
since both CyA and FK 506 work on the peptidyl-prolyl 
isomerase system.6 . 7 although by different routes. Second. 
individual cases appear to be B-ceU lesions that involve the 
tonsillar region. gastrointestinal tract. and allognUt. and 
are associated at least in some cases with active EBV 
infection. These data are currently being analyzed. but the 
features of these lesions appear to be similar to the 
currently accepted spectrum of this disorder. The early 
dissemination of widespread poIyclonal disease in one 
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patient represents an unfortunate but well-established 
manifestation of this disease in a minority of cases. The 
occurrence of tumor in the allograft organ in three of five 
cases is of interest. This may represent a significant 
observation. or may simply be a sampling artifact due to 
small numbers. Allograft involvement is not uncommon in 
cases of PTLD. It may occur alone or as part of dissemi-
nated disease. In the present cases. there was no evidence 
of concurrent PTLD and rejection in the same organ. 
Therefore. the concept that organ rejection and PTLD 
occur at different extremes of immunosuppression remains 
a valid working hypothesis. Finally. the response of the 
tumors to the primary therapeutic approach of local sur-
gery, reduced immunosuppression. and acyclovir is en· 
couraging and appears to be similar to the results obtained 
with other PTLDs.8 In summary. FK 506 is a powerful 
new immunosuppressant that is effective in preventing 
transplant rejection and shows no evidence to date of any 
increase in the risk of developing or succumbing to trans-
plant-associated Iymphoproliferations. 
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